Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | CA1 | P00915 | 2/20 | 0.67 |
| ▸ | CA2 | P00918 | 2/20 | 0.67 |
| ▸ | CA4 | P22748 | 2/20 | 0.67 |
| ▸ | CA6 | P23280 | 2/20 | 0.67 |
| ▸ | CA7 | P43166 | 2/20 | 0.67 |
| ▸ | CA9 | Q16790 | 2/20 | 0.67 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.67 |
| ▸ | CA12 | O43570 | 1/20 | 0.67 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.67 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20676052 | 0.87 | CA1 (0.67) | ALDH1A1CA1CA2CA4CA6 | |
| SCHEMBL19793283 | 0.87 | MAPK1 (0.70) | ALDH1A1CA1CA2CA4CA6 | |
| SCHEMBL9031939 | 0.87 | MAPK1 (0.70) | ALDH1A1CA1CA2CA4CA6 | |
| SCHEMBL3365457 | 0.87 | ALDH1A1 (0.70) | ALDH1A1CA1CA2CA4CA6 | |
| SCHEMBL3365627 | 0.87 | ALDH1A1 (0.70) | ALDH1A1CA1CA2CA4CA6 | |
| SCHEMBL1777398 | 0.87 | ALDH1A1 (0.70) | ALDH1A1CA1CA2CA4CA6 | |
| SCHEMBL20117205 | 0.86 | NPC1 (0.65) | ALDH1A1CA1CA2CA4CA6 | |
| SCHEMBL20116514 | 0.86 | NPC1 (0.65) | ALDH1A1CA1CA2CA4CA6 | |
| SCHEMBL8305710 | 0.85 | ALDH1A1 (0.51) | ALDH1A1CA1CA2CA4CA6 | |
| SCHEMBL6271004 | 0.85 | ALDH1A1 (0.76) | ALDH1A1CA1CA2CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1517674-A2 | PREPARATIONS FOR THE INTRANASAL APPLICATION OF SELECTED CGRP ANTAGONISTS DERIVED FROM AMINO ACIDS AND A METHOD FOR THEIR PRODUCTION | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-03-30 | — | — | EP | claimed |
| WO-2004000289-A2 | PREPARATIONS FOR THE INTRANASAL APPLICATION OF SELECTED CGRP ANTAGONISTS DERIVED FROM AMINO ACIDS AND A METHOD FOR THEIR PRODUCTION | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-12-31 | — | — | WO | claimed |
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | Ananda Scientific, Inc. (US) | 2025-06-19 | — | — | US | disclosed |
| US-11945797-B2 | 1-cyano-pyrrolidine derivatives as dub inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2024-04-02 | — | — | US | disclosed |
| CN-112707893-B | 1-cyanopyrrolidine compounds as USP30 inhibitors | 特殊治疗有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20230286968-A1 | ARYLOXAZOLO SPIRAL RING DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| CN-116457352-A | Aryloxazolo spiro derivatives for the treatment and prophylaxis of hepatitis b virus infection | 豪夫迈·罗氏有限公司 | 2023-07-18 | — | — | CN | disclosed |
| US-20220251041-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-08-11 | — | — | US | disclosed |
| US-11390584-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2022-07-19 | — | — | US | disclosed |
| US-20220177451-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2022-06-09 | — | — | US | disclosed |
| EP-1000620-B1 | Lp(a)-LOWERING AGENTS AND APOPROTEIN (a) PRODUCTION INHIBITORS | TAIHO PHARMACEUTICAL CO LTD (JP) | 2005-12-07 | — | — | EP | disclosed |
| WO-2005032468-A2 | MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-14 | — | — | WO | disclosed |
| US-6166036-A | Lp(a)-lowering agent and apolipoprotein (a) formation suppressing agent | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2000-12-26 | — | — | US | disclosed |
| EP-1000620-A1 | Lp(a)-LOWERING AGENTS AND APOPROTEIN (a) PRODUCTION INHIBTORS | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 2000-05-17 | — | — | EP | disclosed |
| US-6001835-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 1999-12-14 | — | — | US | disclosed |
| EP-0393607-B1 | Phenylcarboxylic acid derivatives having a hetero ring | OTSUKA PHARMA CO LTD (JP) | 1996-02-21 | — | — | EP | disclosed |
| US-5145865-A | Fatty acid, cholesterol synthesis inhibitors; enzyme inhibitors; antilipemic agents | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1992-09-08 | — | — | US | disclosed |
| EP-0393607-A2 | Phenylcarboxylic acid derivatives having a hetero ring | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-10-24 | — | — | EP | disclosed |
| US-4113874-A | PYRROLIDONES, PHARMACEUTICAL COMPOSITIONS THEREWITH AND PROCESSES OF USE THEREOF | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251041-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | ALDH1A1 1264/4885CA1 1593/4885CA2 1529/4885 |
| US-20220177451-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS | USP30, USP28, USP1 | ALDH1A1 719/4885CA1 1660/4885CA2 2893/4885 |
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | CNR2, CNR1, FAAH | ALDH1A1 1320/4885CA1 1695/4885CA2 1050/4885 |
| US-11945797-B2 | 1-cyano-pyrrolidine derivatives as dub inhibitors | USP30, USP28, USP1 | ALDH1A1 719/4885CA1 1660/4885CA2 2893/4885 |
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP1, USP10 | ALDH1A1 1185/4885CA1 1479/4885CA2 2624/4885 |
| US-20230286968-A1 | ARYLOXAZOLO SPIRAL RING DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, CYP4B1, CYP1B1 | ALDH1A1 158/4885CA1 4772/4885CA2 4868/4885 |
| US-11390584-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP20, USP10 | ALDH1A1 1220/4885CA1 1648/4885CA2 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.